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Aim: Over 7 million traumatic brain injuries (TBI) are reported each year in the United States. 
However, treatments and neuroprotection following TBI are limited because secondary injury 
cascades are poorly understood. Lipopolysaccharide (LPS) administration before controlled 
cortical impact can contribute to neuroprotection. However, the underlying mechanisms and 
whether LPS preconditioning confers neuroprotection against closed-head injuries remains 
unclear. Methods: The authors hypothesized that preconditioning with a low dose of LPS 
(0.2 mg/kg) would regulate glial reactivity and protect against diffuse axonal injury induced 
by weight drop. LPS was administered 7 days prior to TBI. LPS administration reduced 
locomotion, which recovered completely by time of injury. Results: LPS preconditioning 
significantly reduced the post-injury gliosis response near the corpus callosum, possibly by 
downregulating the oncostatin M receptor. These novel findings demonstrate a protective 
role of LPS preconditioning against diffuse axonal injury. LPS preconditioning successfully 
prevented neurodegeneration near the corpus callosum, as measured by fluorojade B. 
Conclusion: Further work is required to elucidate whether LPS preconditioning confers 
long-term protection against behavioral deficits and to elucidate the biochemical mechanisms 
responsible for LPS-induced neuroprotective effects.
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INTRODUCTION
Endotoxin preconditioning with lipopolysaccharide 
(LPS) was previously shown to be neuroprotective in 
models of ischemic stroke and traumatic brain injury 
(TBI).[1] The neuroprotective mechanisms of LPS 
remain unclear, particularly with regards to vascular-
mediated effects. Prior studies have studies this 
using contusion-based models of neurotrauma. The 
contusion model irreversibly injures a focal brain 
region, creating a gross structural void associated 
with significant vascular injury.[2] The mechanisms 
of LPS preconditioning are poorly understood 
and have not been studied in a model of diffuse 
axonal injury. There is emerging evidence that pro-
inflammatory regulation is neuroprotective in models 
of neural injury,[3] particularly the regulation of pro-
inflammatory cytokines and microglial phenotype 
changes. Microglia is pleiotropic and transition 
between continuum states. These states are termed 
M1 or M2 depending on the inciting events.[4] 
Microglia may have protective and destructive roles, 
depending on the transition state.[5] The ratio of 
microglial states can predict the subacute outcome 
following injury. M1 microglia are pro-inflammatory 
and can cause long-term deficits.[6] Although LPS 
has been shown to influence astrocyte phenotypes, 
it is not clear whether LPS preconditioning 
modulates microglial phenotypes following diffuse 
axonal injury.[7]
In this study, we investigated the neuroprotective 
effect of LPS preconditioning in a closed-head 
model of diffuse axonal injury for the first time. This 
model of TBI has increased clinical relevance due to 
axonal shearing seen with diffuse neurotrauma.[8] We 
hypothesized that LPS preconditioning would reduce 
inflammation and neurodegeneration following 
diffuse axonal injury. In addition, we predicted that 
LPS preconditioning would regulate the oncostatin 
M receptor (OSMR) in astrocytes and activate the 
M1 microglia phenotype after TBI. TBI promotes 
pro-inflammatory cascades and increases the 
expression of glial fibrillary acidic protein (GFAP);[2,9] 
however, a link between astrocyte regulation and 
the microglia phenotype after TBI has not been 
investigated. In this study, we explored the effect 
of LPS preconditioning on astrocytes and microglia 
and addressed the relationship between cytokine 
receptor expression, astrocyte reactivity, and 
microglial phenotype. Improving our understanding 
of the protective effects of LPS preconditioning may 
accelerate the identification of novel therapeutic 
targets that reduce damage after TBI in individuals 
at risk of concussion.
METHODS
Animals
All procedures involving live animals were approved 
by the Institutional Animal Care and Use Committee 
of West Virginia University and were performed 
according to the principles of the Guide for the 
Care and Use of Laboratory Animals, published 
by the Institute of Laboratory Resources, National 
Research Council (National Institutes of Health 
publication 85-23-2985). Thirty-two male Sprague 
Dawley rats (Hilltop) at 3-4 months of age were 
used in this study. Animals were given standard rat 
chow and water ad libitum.
LPS preconditioning
Rats were pretreated with a single intraperitoneal 
injection of either 0.2 mg/kg LPS (Sigma-Aldrich) or 
0.9% saline (equal volume) 7 days prior to TBI.
Locomotor behavior
After LPS injection, the development of sickness 
behavior was monitored using activity chambers 
as described by Godbout et al.[10] Locomotor 
activity was assessed using an automated activity 
monitoring system (San Diego Instruments, San 
Diego, CA) that recorded beam breaks in the x, y, 
and z planes. Animals were acclimated to the room 
for 1 h prior to testing. Testing chambers consisted of 
square Plexiglass housing and 16 × 16 photobeam 
arrays to detect lateral movements. An 8 × 8 array, 
located above the 16 × 16 array, detected rearing-
associated movements. Activity was quantified over 
30 min and the sum of fine, ambulatory, and rearing 
beam breaks was calculated to give the total number 
of beam breaks. These recordings were completed 
at 2, 4, 24, and 48 h post-injection.
TBI induction
Animals were divided into four groups: sham surgery 
(n = 8), sham surgery with LPS pretreatment (n 
= 8), impact-acceleration injury following saline 
injection (n = 8), and impact-acceleration injury with 
LPS pretreatment (n = 8). Anesthesia was induced 
and maintained using isoflurane (4% induction, 2% 
maintenance). Body temperature was controlled 
with a homeothermic heating blanket equipped 
with a rectal probe. Rats received an impact-
acceleration injury as described previously.[11-13] 
Briefly, a 10-mm diameter and 3-mm thick stainless 
steel disk was affixed to the skull with cyanoacrylate 
between bregma and lambda. The animal was 
placed in a prone position on a foam bed with a 
metal disk directly beneath a 2-m tall Plexiglass tube. 
A 450-g weight was dropped from the top of the 
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tube, striking the metal disk. The disk was then 
removed while the rat was under anesthesia, the 
skull inspected, and the wound sutured. The animal 
was then returned to its cage, which was placed on 
a heating pad. Recovery from injury and anesthesia 
were monitored. No mortality was observed with 
the current injury parameters, and no gross lesions 
were apparent at the time of sacrifice indicating mild 
diffuse axonal injury.
Tissue preparation
Seven days after TBI, animals were anesthetized 
and perfused transcardially with physiological saline. 
Brains were removed and sectioned for histological 
analysis. The frontal cortex was selected for 
histological analysis. Tissue sections were placed 
in 4% paraformaldehyde for a minimum of 1 week. 
Following fixation, brains were processed using 
a Tissue-Tek VIP 5 Automatic Tissue Processor 
(Sakura Finatek, Torrence, CA). Processed tissues 
were paraffin-embedded with Tissue-Tek Tec 5 
embedding system (Sakura Finatek, Torrence, CA) 
and sliced (6 µm) using a Leica RM2235 microtome 
(Leica Microscopes, Buffalo Grove, IL). Sections 
were mounted on glass slides and heat-fixed. 
Immediately prior to staining, tissues were de-
paraffinized with xylene and alcohol washes.[14]
Fluoro-Jade B (FJB) staining
FJB staining was used to identify neural degeneration. 
For FJB labelling, slides were rehydrated through a 
series of alcohol and deionized (dH2O) water rinses 
then incubated in 0.06% potassium permanganate 
for 10 min. Then, slides were rinsed for 2 min in 
dH2O water and incubated with FJB in 0.1% acetic 
acid for 20 min. After staining, slides were washed 
three times in dH2O.
GFAP staining
Tissues were incubated in rabbit anti-cow GFAP 
antibody (Dako, Glostrup, Denmark) at a dilution of 
1:500 in 4% horse serum in Dulbecco’s phosphate 
buffered (DPBS) overnight. Then, tissues were 
washed three times in DPBS and incubated in 
biotinylated anti-rabbit IgG antibody (Vector 
Laboratories, Burlingame, CA) diluted at 1:10,000 
in 4% horse serum in DPBS for 4 h. Next, tissue was 
treated with avidin D-horeradish peroxidase (Vector 
Laboratories, Burlingame, CA) diluted at 1:1,000 in 
DPBS for 1 h. Sections were then stained in DAB 
chromogen solution (Vector Laboratories) for 5 min, 
then tissues were rinsed three times in DPBS and 
dried overnight.
M1 microglia staining
Tissues were incubated in mouse anti-rat CD68 
antibody (AbD Serotec, Kidlington, UK) at a dilution 
of 1:100 in 4% horse serum in DPBS overnight. 
Sections were washed three times in DPBS 
and incubated in a biotinylated anti-mouse IgG 
secondary antibody (Vector Laboratories) diluted 
at 1:10,000 in 4% horse serum in DPBS for 4 h. 
Following secondary antibody incubation, tissues 
were incubated in alkaline phosphatase (Life 
Technology, Carlsbad, CA) diluted at 1:100 in Tris-
bovine serum albumin for 1 h. Then, tissues were 
rinsed three times in DPBS and incubated in Fast 
Blue BB salt (Santa Cruz Biotechnology, Santa 
Cruz, CA) for 5 min. Tissues were washed in xylene, 
mounted using an antifade agent, and cover slipped. 
The slides were sealed with acrylic and stored in the 
dark in a laboratory refrigerator.
GFAP and OSMR staining
Tissues were labelled with rabbit against anti-cow 
GFAP (DAKO) antibody at a dilution of 1:500 in 
5% horse serum in PBS overnight at 4 °C. Next, 
sections were washed twice for 10 min each in 
PBS prior to application of Alexa Fluor 488 goat 
anti-rabbit IgG (Invitrogen, Grand Island, NY) at a 
dilution of 1:100 in PBS for 3 h. Following secondary 
antibody incubation, slides were rinsed twice for 
10 min each in PBS. Then, tissue was labelled 
with a goat anti-mouse OSMR antibody (LifeSpan 
Biosciences, Seattle, WA) at a dilution of 1:200 in 
5% horse serum in PBS overnight at 4 °C. Following 
incubation, slides were rinsed twice for 10 min each 
in PBS prior before applying biotinylated anti-goat 
IgG (Vector Laboratories) at a dilution of 1:10,000 
in 5% horse serum in PBS for 2 h. Next, slides were 
rinsed twice for 10 min each in PBS and incubated 
in Streptavidin Alexa Fluor 546 (Life Technology) 
at a dilution of 1:100 in PBS for 1 h. Slides were 
rinsed in PBS for 10 min and then coverslipped 
with Vectashield Mounting Media containing DAPI 
(Vector Laboratories). Finally, slides were sealed 
with acrylic and stored in the dark in a laboratory 
refrigerator at 4 oC. Images were acquired using 
a Zeiss Axio Imager 2 microscope and quantified 
using ImageJ with standard co-localization 
quantification techniques and the co-localization 
plugin established by Bolte et al.[15]
Histological quantification
Stereology and optical fractionation were used 
to quantify histological results as previously 
described.[16-18] Briefly, a region of interest 
encompassing the corpus callosum was drawn at 
low power using an Olympus AX70 microscope 
and StereoInvestigator software. The region 
encompassing the corpus callosum was chosen 
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because it undergoes robust biochemical changes 
following impact-acceleration TBI.[19] The software 
selected random 75-µm counting frames with 
a depth of 6 µm, and the object of interest was 
marked by an investigator blinded to treatment. The 
region of interest volume was previously identified, 
and the number of cells marked by the observer was 
quantified.
Statistical analysis
Data were analyzed using GraphPad Prism version 
4.0. One-way ANOVA with post-hoc Tukey’s test 
was used to compare histological findings across 
control and various experimental groups. Repeated 
measures two-way ANOVA was used to analyze 
the total activity data. An overlap coefficient of 
0.6 or greater indicated strong co-localization, a 
coefficient between 0.4 and 0.6 indicated medium 
co-localization, and a coefficient < 0.4 indicated 
weak co-localization. A P value of < 0.05 was 
considered statistically significant for all studies.
RESULTS
LPS induces transient acute sickness 
behavior
LPS injection induces systemic sickness in rodents 
as evidenced by an acute reduction in activity.[10,20] 
Figure 1 shows a significant reduction in total activity 
after LPS administration compared with saline-
treated animals based on time (F3,66 = 8.14, P < 
0.001), treatment (F1,66 = 18.67, P < 0.001), and the 
time treatment interaction (F3,66 = 22.92, P < 0.001) 
using two-way repeated measures ANOVA. Total 
activity was reduced by approximately 71% and 
59% at 2 and 4 h post-injection, respectively. This 
was resolved within 24 h, indicating that sickness 
behavior was acute.
LPS preconditioning reduces neuronal 
degeneration and glial activation following 
TBI
Previous studies have demonstrated a 
neuroprotective effect of LPS preconditioning 
following controlled cortical impact injury with 
large vascular insult.[2] Figure 2 shows a significant 
difference in cortical FJB expression between 
experimental groups (F3,32 = 59.79; P < 0.001). LPS 
preconditioning significantly reduced FJB levels 
following TBI according to one-way ANOVA with 
Tukey’s post-hoc test (q = 8.50, P < 0.001). No 
difference was observed between sham-injured and 
LPS-treated animals (q = 0.13, P > 0.05), indicating 
that peripheral administration of LPS did not induce 
neurodegeneration.
GFAP expression in the cortex differed significantly 
between experimental groups (F3,32 = 57.92; P < 
0.001) [Figure 3]. LPS preconditioning significantly 
reduced GFAP levels after TBI according to one-
way ANOVA and post-hoc Tukey’s test (q = 8.70, 
P < 0.001). No difference was observed between 
sham-injured and LPS-treated animals (q = 2.89, P 
> 0.05), indicating that peripheral administration of 
LPS did not activate astrocytes.
LPS preconditioning reduces M1 microglia 
activation after TBI
To investigate the effect of LPS preconditioning on 
classically activated microglia, CD68 expression 
was quantified by stereology. Figure 4 shows a 
significant difference in CD68 expression between 
experimental groups (F3,32 = 28.22; P < 0.001). 
The presence of M1 microglia (CD68 expression) 
was significantly reduced after TBI following LPS 
preconditioning compared with no LPS pretreatment 
according to one-way ANOVA with post-hoc Tukey’s 
test (q = 9.77, P < 0.001). Importantly, no significant 
differences in CD68 expression were observed 
between injured animals with LPS preconditioning 
and sham-injured animals (q = 2.121, P > 0.05). 
These findings were consistent with IBA-1 staining 
for undifferentiated microglia, which showed a 
qualitative reduction in LPS pre-conditioned animals 
[Figure 5].
LPS preconditioning reduces OSMR 
expression in astrocytes after TBI
One of the primary mechanisms for regulating 
astrocyte activation is neuropoietic cytokine signaling 
through the gp130 receptor-signaling complex.[21] TBI 
associated with significant vascular injury upregulates 
members of the neuropoietic cytokine family, including 
Figure 1: Total locomotor activity after LPS injection by number of 
beam breaks at 2, 4, 24, and 48 h after injection. Acute sickness 
was present at 2 and 4 h but resolved by 24 h. ***P < 0.001. LPS: 
lipopolysaccharide
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OSMR.[22] We observed significant OSMR upregulation 
following diffuse axonal injury [Figure 6]. OSMR 
expression differed significantly between experimental 
groups (F3,32 = 11.80; P < 0.05). OSMR expression 
was reduced after TBI in LPS pre-conditioned animals 
compared with no LPS pretreatment according to one-
way ANOVA with post-hoc Tukey’s test (q = 6.51, P 
< 0.05). No difference was observed between LPS-
treated animals and sham-injured rats at this time point 
(q = 0.45, P > 0.05).
Figure 2: Neural degeneration increased following traumatic brain injury. Fluoro jade B significantly increased following traumatic brain 
injury but LPS preconditioning ameliorated this effect. Scale bar = 50 µm. ***P < 0.001. LPS: lipopolysaccharide; TBI: traumatic brain 
injuries; FJB: Fluoro-Jade B
Figure 3: Astrocyte reactivity increased following TBI. GFAP increased significantly following TBI but LPS preconditioning ameliorated the 
effect. Scale bar = 50 µm. ***P < 0.001. LPS: lipopolysaccharide; TBI: traumatic brain injuries; GFAP: glial fibrillary acidic protein
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GFAP expression was quantified to measure 
astrocyte activation and was significantly different 
between experimental groups (F3,32 = 6.30; P < 0.05) 
[Figure 6]. LPS preconditioning significantly reduced 
GFAP expression after TBI as shown by one-way 
ANOVA and post-hoc Tukey’s test (q = 4.44; P < 
0.05). Again, no difference was observed between 
LPS-treated and sham-injured rats at this time point 
(q = 0.45; P > 0.05). Importantly, there was a strong 
correlation between GFAP and OSMR expression 
evidenced by the yellow overlay (overlap coefficient 
r = 0.722), indicating a high degree of overlap within 
Figure 4: M1 microglia activation increased significantly following TBI. CD68 was significantly increased following TBI but LPS 
preconditioning ameliorated the effect. Scale bar = 50 µm. ***P < 0.001. LPS: lipopolysaccharide; TBI: traumatic brain injuries
Figure 5: No significant differences were observed in IBA-1 microglia staining between groups. LPS: lipopolysaccharide; TBI: traumatic 
brain injuries
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the same astrocyte. This was partially mitigated by 
LPS preconditioning (overlap coefficient r = 0.478).
DISCUSSION
Diffuse axonal injury is induced consistently by the 
weight drop method without producing a grossly 
visible lesion.[23] We have previously confirmed that 
the injury parameters used in this study induce 
diffuse axonal injury by measuring β-amyloid 
precursor protein expression.[24] The weight drop 
model is ideal for testing neuroprotective strategies 
because it induces consistent axonal damage and a 
characteristic progression of traumatic axonal injury in 
rodents.[25] Axonal injury reduces cerebral blood flow 
following neurotrauma.[26] Therefore, it is potentially 
worthwhile to investigate compounds that contribute 
to vascular preconditioning. Vascular preconditioning 
by heat activation reduces TBI severity and the extent 
of axonal damage by selectively activating hypoxia-
inducible factor 1α.[27] Low-dose LPS pretreatment 
has also been used for successful vascular 
preconditioning in penetrating models of TBI.[28] 
One proposed mechanism for LPS is a reduction of 
inflammatory mediators before injury.[29] Inflammatory 
mediators can activate gliosis.[30]
In this study, we show for the first time that low-
dose LPS preconditioning is protective in a 
closed-head model of diffuse axonal injury. LPS 
preconditioning has previously been shown to be 
protective in penetrating models, but there was 
significant vascular disruption in these models and 
they were generally more severe than our model 
of diffuse axonal injury. The findings of the present 
study are significant in that they demonstrate that 
LPS preconditioning regulates microglia and OSMR 
in a model of diffuse axonal injury. Furthermore, 
these protective effects are sustained at one week 
post-injury. Protection was established in a mild 
injury model with no mortality or gross pathological 
changes, indicating that LPS pretreatment may also 
protect against mild neurotrauma.
Longhi et al.[2] showed that LPS preconditioning 
alters IL-6 and OSM expression following TBI. In 
this study, we demonstrated that LPS may exert a 
neuroprotective effect against diffuse axonal injury 
through modulation of neurodegeneration and the 
gliosis response. This supports the notion that LPS 
induces neuroprotective effects originally proposed 
by Longhi et al.[2] We observed a transient acute 
sickness induced by LPS pretreatment. However, 
LPS preconditioning had the following effects, 
including: reduced FJB, OSMR, GFAP, and CD68 
expression. Decreased FJB staining was indicative 
of reduced neurodegeneration. This has been 
demonstrated in vitro by Zhu et al.,[31] and our 
findings have now confirmed this in vivo. Increased 
Figure 6: Colocalization of GFAP and OSMR with DAPI. GFAP (green) and OSMR (red) were significantly increased in the same cells 
(merged yellow) following TBI. LPS preconditioning prevented OSMR upregulation. *P < 0.05. LPS: lipopolysaccharide; TBI: traumatic brain 
injuries; GFAP: glial fibrillary acidic protein; OSMR: oncostatin M receptor
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FJB staining has been associated with motor deficits 
following TBI.[32] In a future study, we plan to look at 
the role of LPS preconditioning in preventing motor 
deficits following TBI.
Reactive astrocytes can inhibit axonal regrowth 
after an axon is severed.[33] OSM activity increases 
in demyelinated areas, leading to an upregulation 
of OSMR. This upregulation indicates a loss 
of detrimental connectivity,[22] while decreased 
OSMR indicates preservation of myelin integrity 
and axonal tracts. Our findings show that LPS 
preconditioning significantly reduces OSMR levels 
[Figure 7]. Interestingly, GFAP expression was also 
downregulated, which may reflect an interaction 
between LPS and toll like receptor 4 (TLR4). Low-
dose LPS administration can stimulate TLR4, 
which activates signaling cascades to suppress 
innate immunity and astrocyte activation. These 
cell-signaling events permit axonal regeneration 
without the threat of glial scar formation.[34] As long 
as myelin integrity is maintained, neurons can 
re-innervate most of their lost connections. The 
clinical use of LPS preconditioning is obviously 
limited because injury cannot be predicted, but 
targeting TLR4 pharmacologically might represent 
a reasonable strategy. Further work is needed to 
determine the exact interactions between low-dose 
LPS administration and TLR4.
In addition to effects on astrocytosis, LPS 
preconditioning has also been associated with 
microglial changes. LPS can promote the infiltration 
of macrophages into the brain, which helps resolve 
the microglia response after diffuse traumatic 
axonal injury.[35] Microglia is broadly grouped into 
pro-inflammatory M1 microglia and pro-survival 
anti-inflammatory M2 microglia.[36] The balance of 
M1 to M2 microglia is tightly controlled following 
injury.[37] M1 microglia can exacerbate axonal injury, 
thereby limiting functional recovery. We showed 
that LPS preconditioning selectively inhibited 
the M1 response. LPS caused an acute increase 
in pro-inflammatory markers, which may signal 
peripheral macrophages to cross brain vasculature 
by chemotaxis. Peripheral macrophages alter the 
inflammatory mileu of the brain while attenuating 
microglial activity.[38] In contrast, M2 microglia 
are largely unaffected due to the earlier peak of 
activation after injury, which we have shown using 
non-differentiated IBA-1 imaging.[39] The brain 
establishes functional recovery by shifting the 
balance away from M1 microglia.
LPS has been associated with inflammation. 
Suppressing inflammation limits the effect of LPS on 
human physiology.[40] LPS increases tissue necrosis 
factor α, interleukin 6, and interleukin 1 expression 
[Figure 6].[41] LPS preconditioning reduces neuronal 
loss and microglia activation in other injury models, 
such as global hypoxia.[42] In the present study, LPS 
preconditioning also significantly reduced neuronal 
degeneration following diffuse axonal injury. 
Chronic LPS-mediated inflammation is detrimental 
Figure 7: Hypothetical schematic showing the mechanism of LPS action. LPS: lipopolysaccharide; TBI: traumatic brain injuries; OSMR: 
oncostatin M receptor; TLR4: toll like receptor 4
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to the brain, but acute LPS preconditioning provides 
“inflamaprepping” that primes the nervous system 
for response to injury.[43] Although inflamaprepping 
is not a universal to all TBIs, it offers a potential 
therapeutic advantage for a certain subset of 
individuals, namely soldiers and athletes. Soldiers 
and athletes are at increased risk of concussion and 
subconcussive injury. Prevent injury and enhancing 
recovery in these individuals is receiving increasing 
attention. Inflamaprepping with a systemically 
injected agent such as low-dose LPS is clinically 
feasible and may limit gliosis and subsequent 
glial scar formation by preparing the brain for 
trauma. Ultimately this would facilitate rapid 
axonal regeneration guided by preserved myelin 
tracts. In the current study, we have shown that 
inflamaprepping inhibits gliosis, downregulates the 
OSMR receptor, and shifts the microglia phenotype 
balance away from the pro-inflammatory M1 
state, thereby decreasing neurodegeneration and 
promoting neuroprotection. The benefits of this 
neuroprotection on preventing behavioral decline 
will be investigated in a future study.
There are some limitations to the present study. 
Firstly, we did not assess post-injury behavior. Based 
on our histopathologic findings, we expect that 
LPS preconditioning prevents behavioral deficits 
following TBI, but needs to be verified in a future 
study. Secondly, we did not or examine glial marker 
expression later than 7 days after LPS treatment. 
This data would have indicated the current state of 
gliosis and inflammation at the time of injury.
In conclusion, we have shown for the first time that 
low-dose LPS preconditioning has protective effects 
in a diffuse axonal injury model. LPS preconditioning 
prevented both astrocyte and microglia activation 
through downregulation of the OSMR receptor. 
This protective effect was verified by reduced 
FJB staining, indicating decreased degeneration. 
Preconditioning and inflamaprepping may be viable 
targets for TBI treatment and may prevent long-
term behavioral sequelae in patients. Future work 
will examine the long-term functional changes that 
lead to neurodegenerative disease progression 
and tauopathies. We will elucidate whether LPS 
preconditioning reduces tau hyperphosphorylation 
and improves behavior following repetitive 
injury. Mediating the gliosis response with LPS 
preconditioning may decrease neurodegeneration 
and slow the development of tauopathy.
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